What Is Blood Type A?

In individuals with blood type A, the glycoprotein on the surface of red blood cells contains the A antigen, which is formed by the addition of N-acetyl-galactosamine to the glycoprotein by A transferase. When an individual with blood type A is exposed to red blood cells of blood type B or AB that correspond to a B antigen, their immune system produces anti-B antibodies, also known as anti-B hemagglutinins. These antibodies recognize and bind to the B antigen, leading to agglutination of red blood cells and an immune response that may trigger a transfusion reaction or organ transplant rejection. Therefore, in blood transfusion and organ transplantation, it is necessary to accept blood or organs that match one's blood type to avoid adverse reactions. The A antigen also exists on the cell surface of other tissues, organs, and fluids such as saliva and tears.

Fig.1 Antigens and antibodies of the ABO system. (Wikipedia)

Blood Type A Sugar Chain-based Cell Surface Glycoengineering Services at CD BioGlyco

• Gene editing

CD BioGlyco uses gene editing technology to introduce or knock out genes related to blood type A, thereby achieving the synthesis or elimination of blood type A sugar chains on the cell surface.

• Glycotransferase-mediated modification

CD BioGlyco uses a specific glycosyltransferase to catalyze a reaction to introduce or modify the blood type A sugar chain structure on the cell surface. For example, acetylation, sulfation, methylation, etc., which may change the biological properties, stability, or recognition specificity of sugar chains.

• Protein glycosylation modification

CD BioGlyco provides connection services between blood type A sugar chains and target proteins on the cell surface to achieve glycosylation modification of proteins.

• Analysis and identification of blood type A sugar chains on cell surface

CD BioGlyco provides chromatography, mass spectrometry, and other analysis methods for blood type A sugar chains to identify and quantitatively analyze the sugar chain structure.

Fig.2 Blood type A sugar chain-based cell surface glycoengineering services. (CD BioGlyco)

Applications

• Blood group antigens: Introducing type A blood sugar chains or related to other blood group antigens simulate the existence of antigens, and study the interaction mechanism with other molecules (such as pathogens, and proteins).
• Immune response: In immune cell recognition and inflammatory response regulation, sugar chain-mediated immune response mechanisms, are studied by modifying the cell surface with type A glucose chains, such as cell recognition, phagocytosis, and inflammatory signal transduction.
• Cell and drug study: Introducing type A blood sugar chains to the cell surface changes its surface character, which is applied in the development of cells and drug delivery systems to improve targeting and therapeutic effects.

Advantages

• Multidisciplinary technical team: We have multidisciplinary technical talents providing cell surface glycoengineering services, working collaboratively, and solving complex technical and application problems.
• Diversified service scope: CD BioGlyco provides a variety of services, supporting cell culture, sugar chain analysis, and glycosyl modification of cell surface, and provides clients with a full range of cell surface glycoengineering solutions.

CD BioGlyco has rich professional knowledge and practical experience in the field of Cell Surface Glycoengineering and provides high-level custom blood type A sugar chain-based cell surface glycoengineering services. Please feel free to contact us in time if you would like further consultation on service content.